It remains important to interrogate how structural discrimination influences the collection of patient-reported outcomes.
Studies suggest that the majority of pediatric patients with cancer and COVID-19 experience mild disease — rather than severe disease — as a result of infection with the novel virus.
Upfront metastasis-directed therapy may be a viable treatment approach in patients with oligorecurrent disease, particularly those who wish to defer systemic therapy.
Oncopeptides will seek accelerated approval from the FDA after melflufen demonstrates a manageable safety profile.
The increase is thought to be related to environmental factors.
It was determined that ICIs were less efficacious in Taiwanese patients with melanoma.
Black patients were half as likely to receive remdesivir as White patients, according to researchers from the CCC19.
Combining 2 predictors yielded better results than just using 1.
Recent research suggests cancer patients who have undergone genetic testing for inherited or acquired mutations were more likely to have prolonged overall survival than patients who did not,
Researchers examine how far follicular lymphoma treatment has come, what limitations still remain, and where the management of the disease is headed.
So far, prostate cancer immunotherapy has shown only modest benefits. To greatly improve outcomes, immunotherapy will need to be combined with other treatments, according to the authors of a recent review.
Regardless of the efficacy of immune checkpoint inhibition in some settings, many cancers will not respond to treatment with them.
Some tyrosine kinase inhibitors may cause a hyperinflammatory response.
Men with GPS scores greater than 40 had a poor disease prognosis after surgery and their disease was likely to behave like that of high-risk patients.
COVID-19 has brought unprecedented stress to society at large and perhaps most of all to frontline healthcare teams in a variety of settings. We spoke to an expert about teamwork during such trying times.